Research programme: vascular endothelial growth factor inhibitors - Beta PharmaAlternative Names: BP 702001; BP 703010
Latest Information Update: 16 Jul 2016
At a glance
- Originator Zhejiang Beta Pharma
- Mechanism of Action Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China
- 07 Jul 2009 Preclinical trials in Cancer in China (unspecified route)